Is it time to revise the normal range of serum uric acid levels?

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 9, 2014, Pages 1295-1306

  Desideri, G ^a   Castaldo, G ^b,c   Lombardi, A ^d   Mussap, M ^e   Testa, A ^d   Pontremoli, R ^f   Punzi, L ^g   Borghi, C ^h  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^d Laboratory Medicine Unit IRCCS AOU San Martino IST University Hospital ^*

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cardiovascular disease; Gout; Hyperuricemia; Renal disease; Uric acid

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; IMMUNOGLOBULIN G ANTIBODY; NITRIC OXIDE SYNTHASE; URATE; URIC ACID; BIOLOGICAL MARKER;

ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; IMMUNOGLOBULIN A NEPHROPATHY; INSULIN RESISTANCE; KIDNEY PROXIMAL TUBULE; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL VALUE; PHAGOCYTOSIS; PKA; PURINE METABOLISM; RHEUMATOID ARTHRITIS; SODIUM INTAKE; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; AGE; BLOOD; FEMALE; MALE; NORMAL HUMAN; PREDICTIVE VALUE; PREVALENCE; REFERENCE VALUE; RISK FACTOR; SEX DIFFERENCE;

AGE FACTORS; BIOLOGICAL MARKERS; FEMALE; GOUT; HEALTHY VOLUNTEERS; HUMANS; HYPERURICEMIA; MALE; PREDICTIVE VALUE OF TESTS; PREVALENCE; REFERENCE VALUES; RISK FACTORS; SEX FACTORS; URIC ACID;

EID: 84902167649     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. WALLACE KL, RIEDEL AA, JOSEPH-RIDGE N, WORTMANN R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31: 1582-1587. (Pubitemid 39006641)
2. RODDY E, DOHERTY M. Epidemiology of gout. Arthritis Res Ther 2010; 12: 223.
3. KLEMP P, STANSFIELD SA, CASTLE B, ROBERTSON MC Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56: 22-26. (Pubitemid 27060568)
4. MIAO Z, LI C, CHEN Y, ZHAO S, WANG Y, WANG Z, CHEN X, XU F, WANG F, SUN R, HU J, SONG W, YAN S, WANG CY. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol 2008; 35: 1859-1864.
5. TRIFIRÒ G, MORABITO P, CAVAGNA L, FERRAJOLO C, PECCHIOLI S, SIMONETTI M, BIANCHINI E, MEDEA G, CRICELLI C, CAPUTI A P, MAZZAGLIA G. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: A nationwide population-based study. Ann Rheum Dis 2013; 72: 694-700.
6. ZHU Y, PANDYA BJ, CHOI HK Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63: 3136-3141.
7. CHOI HK, ATKINSON K, KARLSON EW, CURHAN G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health Professionals Follow-up Study. Arch Intern Med 2005; 165: 742-748. (Pubitemid 40569426)
8. CHOI HK, ATKINSON K, KARLSON EW, WILLETT W, CURHAN G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-1103. (Pubitemid 38298989)
9. CHOI HK, ATKINSON K, KARLSON EW, WILLETT W, CURHAN G. Alcohol intake and risk of incident gout in men: A prospective study. Lancet 2004; 363: 1277-1281. (Pubitemid 38496489)
10. CHOI HK, CURHAN G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008; 336: 309-312. (Pubitemid 351278368)
11. CHOI JW, FORD ES, GAO X, CHOI HK Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008; 59: 109-116. (Pubitemid 351171885)
12. FISHBERG AM. The interpretation of blood uric acid in hypertension. Arch Intern Med (Chic) 1924; 34: 503-507.
13. GLYNN RJ, CAMPION EW, SILBERT JE Trends in serum uric acid levels 1961-1980. Arthritis Rheum 1983; 26: 87-93. (Pubitemid 13175206)
14. RICHETTE P, BARDIN T. Gout. Lancet 2010; 375: 318-328.
15. GRASSI D, FERRI L, DESIDERI G, DI GIOSIA P, CHELI P, DEL PINTO R, PROPERZI G, FERRI C. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des 2013; 19: 2432-2438.
16. TERKELTAUB R, BUSHINSKY DA, BECKER MA Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther 2006; 8(Suppl 1): S4.
17. SO A, THORENS B. Uric acid transport and disease. J Clin Invest 2010; 120: 1791-1799.
18. ENOMOTO A, KIMURA H, CHAIROUNGDUA A, SHIGETA Y, JUTABHA P, CHA SH, HOSOYAMADA M, TAKEDA M, SEKINE T, IGARASHI T, MATSUO H, KIKUCHI Y, ODA T, ICHIDA K, HOSOYA T, SHIMOKATA K, NIWA T, KANAI Y, ENDOU H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-452. (Pubitemid 34563537)
19. HAMADA T, ICHIDA K, HOSOYAMADA M, MIZUTA E, YANAGIHARA K, SONOYAMA K, SUGIHARA S, IGAWA O, HOSOYA T, OHTAHARA A, SHIGAMASA C, YAMAMOTO Y, NINOMIYA H, HISATOME I. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008; 21: 1157-1162.
20. PASCUAL E, PERDIGUERO M. Gout, diuretics and the kidney. Ann Rheum Dis 2006; 65: 981-982. (Pubitemid 44133257)
21. NEOGI T. Clinical practice. Gout. N Engl J Med 2011; 364: 443-452.
22. SIMKIN PA. Urate excretion in normal and gouty men. Adv Exp Med Biol 1977; 76B: 41-45.
23. PROCTOR P. Similar functions of uric acid and ascorbate in man? Nature 1970; 228: 868.
24. HINK HU, SANTANAM N, DIKALOV S, MCCANN L, NGUYEN AD, PARTHASARATHY S, HARRISON DG, FUKAI T. Peroxidase properties of the extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 2002; 22: 1402-1408.
25. WATANABE S, KANG DH, FENG L, NAKAGAWA T, KANELLIS J, LAN H, MAZZALI M, JOHNSON RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355-360. (Pubitemid 35006723)
26. EATON SB, KONNER M. Paleolithic nutrition. A consideration of its nature and current implications. N Engl J Med 1985; 312: 283-289. (Pubitemid 15199367)
27. JOHNSON RJ, SAUTIN YY, OLIVER WJ, RONCAL C, MU W, GABRIELA SANCHEZ-LOZADA L, RODRIGUEZ-ITURBE B, NAKAGAWA T, BENNER SA. Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society? J Comp Physiol B 2009; 179: 67-76.
28. NAKAGAWA T, TUTTLE KR, SHORT RA, JOHNSON RJ Hypothesis: fructose-induced hyperuricemia as a casual mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 2005; 1: 80-86.
29. KHOSLA UM, ZHARIKOV S, FINCH JL, NAKAGAWA T, RONCAL C, MU W, KROTOVA K, BLOCK ER, PRABHAKAR S, JOHNSON RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742. (Pubitemid 40577708)
30. SAUTIN YY, NAKAGAWA T, ZHARIKOV S, JOHNSON RJ Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293: C584-C596. (Pubitemid 47235197)
31. OROWAN E. The origin of man. Nature 1955; 175: 683-684.
32. INOUYE E, PARK KS, ASAKA A. Blood uric acid level and IQ: A study in twin families. Acta Genet Med Gemellol (Roma) 1984; 33: 237-242. (Pubitemid 15126090)
33. SHI Y, EVANS JE, ROCK KL Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-521. (Pubitemid 37237047)
34. HU DE, MOORE AM, THOMSEN LL, BRINDLE KM Uric acid promotes tumor immune rejection. Cancer Res 2004; 64: 5059-5062. (Pubitemid 39006518)
35. KANELLIS J, KANG DH Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005; 25: 39-42. (Pubitemid 40128147)
36. WU XW, MUZNY DM, LEE CC, CASKEY CT Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992; 34: 78-84.
37. JOHNSON RJ, RIDEOUT BA Uric acid and diet-insights into the epidemic of cardiovascular disease. N Engl J Med 2004; 350: 1071-1073. (Pubitemid 38298984)
38. JOHNSON RJ, TITTE S, CADE JR, RIDEOUT BA, OLIVER WJ Uric acid, evolution and primitive cultures. Semin Nephrol 2005; 25: 3-8. (Pubitemid 40128142)
39. NING TC, KEENAN RT Gout in the elderly. Clinical Geriatrics 2011; 19: 20-25.
40. MCLEAN L. The pathogenesis of gout. In: Hochberg M, ed. Rheumatology: Edinburgh: Mosby, 2003; pp. 1903-1918.
41. PÉTRILLI V, MARTINON F. The inflammasome, autoinflammatory diseases, and gout. Joint Bone Spine 2007; 74: 571-576. (Pubitemid 350236009)
42. CAMPION EW, GLYNN RJ, DELABRY LO Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421-426.
43. BECKER MA, LEVINSON D. Clinical gout and pathogenesis of hyperuricemia. In: Koopman WJ, ed. Arthritis and allied conditions, 13th edn. Baltimore: Williams & Wilkins, 1996; pp. 2041-2072.
44. BOMALASKI JS, LLUBERAS G, SCHUMACHER HR JR. Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum 1986; 29: 1480-1484. (Pubitemid 17003886)
45. ROUAULT T, CALDWELL DS, HOLMES EW Aspiration of the asymptomatic metatarsophalangeal joint in gout patients and hyperuricemic controls. Arthritis Rheum 1982, 25: 209-212. (Pubitemid 12170280)
46. CARTER JD, KEDAR R P, ANDERSON SR, OSORIO AH, ALBRITTON NL, GNANASHANMUGAM S, VALERIANO J, VASEY FB, RICCA LR. An analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs. Rheumatology 2009; 48: 1442-1446.
47. PINEDA C, AMEZCUA-GUERRA LM, SOLANO C, RODRIGUEZ-HENRÍQUEZ P, HERNÁNDEZ-DÍAZ C, VARGAS A, HOFMANN F, GUTIÉRREZ M. Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: An ultrasound controlled study. Arthritis Res Ther 2011; 13: R4.
48. WRIGHT SA, FILIPPUCCI E, MCVEIGH C, GREY A, MCCARRON M, GRASSI W, WRIGHT GD, TAGGART AJ. Highresolution ultrasonography of the first metatarsal phalangeal joint in gout: A controlled study. Ann Rheum Dis 2007; 66: 859-864. (Pubitemid 46999784)
49. THIELE RG, SCHLESINGER N. Diagnosis of gout by ultrasound. Rheumatology (Oxford) 2007; 46: 1116-1121. (Pubitemid 47050614)
50. THIELE RG, SCHLESINGER N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int 2010; 30: 495-503.
51. KHANNA D, FITZGERALD JD, KHANNA P P, BAE S, SINGH MK, NEOGI T, PILLINGER MH, MERILL J, LEE S, PRAKASH S, KALDAS M, GOGIA M, PEREZ-RUIZ F, TAYLOR W, LIOTÉ F, CHOI H, SINGH JA, DALBETH N, KAPLAN S, NIYYAR V, JONES D, YAROWS SA, ROESSLER B, KERR G, KING C, LEVY G, FURST DE, EDWARDS NL, MANDELL B, SCHUMACHER HR, ROBBINS M, WENGER N, TERKELTAUB R; AMERICAN COLLEGE OF RHEUMATOLOGY. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012; 64: 1431-1446.
52. ZHANG W, DOHERTY M, BARDIN T, PASCUAL E, BARSKOVA V, CONAGHAN P, GERSTER J, JACOBS J, LEEB B, LIOTÉ F, MCCARTHY G, NETTER P, NUKI G, PEREZ-RUIZ F, PIGNONE A, PIMENTÃO J, PUNZI L, RODDY E, UHLIG T, ZIMMERMANN- GÒRSKA I; EULAR STANDING COMMITTEE FOR INTERNATIONAL CLINICAL STUDIES INCLUDING THERAPEUTICS. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ES-CISIT). Ann Rheum Dis 2006; 65: 1312-1324. (Pubitemid 44620440)
53. MANARA M, BORTOLUZZI A, FAVERO M, PREVETE I, SCIRÈ CA, BIANCHI G, BORGHI C, CIMMINO MA, D'AVOLA GM, DESIDERI G, DI GIACINTO G, GOVONI M, GRASSI W, LOMBARDI A, MARANGELLA M, MATUCCI CERINIC M, MEDEA G, RAMONDA R, SPADARO A, PUNZI L, MINISOLA G. Italian Society of Rheumatology recommendations for the management of gout. Reumatismo 2013; 65: 4-21.
54. BECKER MA, SCHUMACHER HR, MACDONALD PA, LLOYD E, LADEMACHER C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009; 36: 1273-1282.
55. FEIG DI, KANG DH, JOHNSON RJ Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
56. GRAYSON PC, KIM SY, LAVALLEY M, CHOI HK Hyperuricemia and incident hypertension: A systemic review and meta-analysis. Arthritis Care Res 2011; 63: 102-110.
57. FEIG DI, JOHNSON RJ Hyperuricemia in childhood primary hypertension. Hypertension 2003; 42: 247-252. (Pubitemid 37093468)
58. FEIG DI, SOLETSKY B, JOHNSON RJ Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 2008; 300: 924-932.
59. TSOULI SG, LIBEROPOULOS EN, MIKHAILIDIS D P, ATHYROS VG, ELISAF MS Elevated serum uric acid levels in metabolic syndrome: An active component or an innocent bystander? Metabolism 2006; 55: 1293-1301. (Pubitemid 44354944)
60. KODAMA S, SAITO K, YACHI Y, ASUMI M, SUGAWARA A, TOTSUKA K, SAITO A, SONE H. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009; 32: 1737-1742.
61. DEHGHAN A, VAN HOEK M, SIJBRANDS EJ, HOFMAN A, WITTEMAN JC High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008; 31: 361-362. (Pubitemid 351213351)
62. MASUO K, KAWAGUCHI H, MIKAMI H, OGIHARA T, TUCK ML Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42: 474-480. (Pubitemid 37237341)
63. LV Q, MENG X F, HE F F, CHEN S, SU H, XIONG J, GAO P, TIAN XJ, LIU JS, ZHU ZH, HUANG K, ZHANG C. High serum uric acid and increased risk of type 2 diabetes: A systemic review and meta-analysis of prospective cohort studies. PLoS One 2013; 8: e56864.
64. VIAZZI F, LEONCINI G, VERCELLI M, DEFERRARI G, PONTREMOLI R. Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study. Diabetes Care 2011; 34: 126-128.
65. FANG J, ALDERMAN MH Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-2410. (Pubitemid 30257539)
66. FREEDMAN DS, WILLIAMSON D F, GUNTER EW, BYERS T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141: 637-644.
67. IOACHIMESCU AG, BRENNAN DM, HOAR BM, HAZEN SL, HOOGWERF BJ Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: A preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008; 58: 623-630. (Pubitemid 351294901)
68. ANKER SD, DOEHNER W, RAUCHHAUS M, SHARMA R, FRANCIS D, KNOSALLA C, DAVOS CH, CICOIRA M, SHAMIM W, KEMP M, SEGAL R, OSTERZIEL KJ, LEYVA F, HETZER R, PONIKOWSKI P, COATS AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-1997. (Pubitemid 36506072)
69. KUO CF, SEE LC, LUO S F, KO YS, LIN YS, HWANG JS, LIN CM, CHEN HW, YU KH. Gout: An independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 2010; 49: 141-146.
70. KRISHNAN E, SVENDSEN K, NEATON JD, GRANDITS G, KULLER LH; MRFIT RESEARCH GROUP. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008; 168: 1104-1110. (Pubitemid 351749228)
71. CHOI HK, CURHAN G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900. (Pubitemid 47300913)
72. STACK AG, HANLEY A, CASSERLY L F, CRONIN CJ, ABDALLA AA, KIERNAN TJ, MURTHY BV, HEGARTY A, HANNIGAN A, NGUYEN HT. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 2013; 106: 647-658.
73. NISKANEN LK, LAAKSONEN DE, NYYSSÖNEN K, ALFTHAN G, LAKKA HM, LAKKA TA, SALONEN JT Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: A prospective cohort study. Arch Intern Med 2004; 164: 1546-1551. (Pubitemid 38970476)
74. VERDECCHIA P, SCHILLACI G, REBOLDI G, SANTEUSANIO F, PORCELLATI C, BRUNETTI P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000; 36: 1072-1078.
75. SMINK PA, BAKKER SJ, LAVERMAN GD, BERL T, COOPER ME, DE ZEEUW D, LAMBERS HEERSPINK HJ. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: A post-hoc analysis of the RENAAL and IDNT trials. J Hypertens 2012; 30: 1022-1028.
76. STRUTHERS AD, DONNAN PT, LINDSAY P, MCNAUGHTON D, BROOMHALL J, MACDONALD TM Effect of allopurinol on mortality and hospitalisations in chronic heart failure: A retrospective cohort study. Heart 2002; 87: 229-234. (Pubitemid 34177675)
77. ZOPPINI G, TARGHER G, NEGRI C, STOICO V, PERRONE F, MUGGEO M, BONORA E. Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes Care 2009; 32: 1716-1720.
78. WEI L, MACKENZIE IS, CHEN Y, STRUTHERS AD, MACDONALD TM Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol 2011; 71: 600-607.
79. STETTEN D JR, HEARON JZ Intellectual level measured by army classification battery and serum uric acid concentration. Science 1959; 129: 1737.
80. BROOKS GW, MUELLER E. Serum urate concentrations among university professors: relation to drive, achievement, and leadership. JAMA 1966; 195: 415-418.
81. BLOCH S, BRACKENRIDGE CJ Psychological, performance and biochemical factors in medical students under examination stress. J Psychosom Res 1972; 16: 25-33.
82. SCHRETLEN DJ, INSCORE AB, JINNAH HA, RAO V, GORDON B, PEARLSON GD Serum uric acid and cognitive function in community-dwelling older adults. Neuropsychology 2007; 21: 136-140. (Pubitemid 46066213)
83. AFSAR B, ELSURER R, COVIC A, JOHNSON RJ, KANBAY M. Relationship between uric acid and subtle cognitive dysfunction in chronic kidney disease. Am J Nephrol 2011; 34: 49-54.
84. RUGGIERO C, CHERUBINI A, LAURETANI F, BANDINELLI S, MAGGIO M, DI IORIO A, ZULIANI G, DRAGONAS C, SENIN U, FERRUCCI L. Uric acid and dementia in community-dwelling older persons. Dement Geriatr Cogn Disord 2009; 27: 382-389.
85. SCHRETLEN DJ, INSCORE AB, VANNORSDALL TD, KRAUT M, PEARLSON GD, GORDON B, JINNAH HA Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; 69: 1418-1423. (Pubitemid 47511463)
86. VANNORSDALL TD, JINNAH HA, GORDON B, KRAUT M, SCHRETLEN DJ Cerebral ischemia mediates the effect of serum uric acid on cognitive function. Stroke 2008; 39: 3418-3420.
87. KIM SY, GUEVARA J P, KIM KM, CHOI HK, HEITJAN D F, ALBERT DA. Hyperuricemia and risk of stroke: A systematic review and meta-analysis. Arthritis Rheum 2009; 61: 885-892.
88. STORHAUG HM, NORVIK J V, TOFT I1, ERIKSEN BO, LØCHEN ML, ZYKOVA S, SOLBU M, WHITE S, CHADBAN S, JENSSEN T. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: A gender specific analysis from The Tromsø Study. BMC Cardiovasc Disord 2013; 13: 115.
89. MAZZALI M, HUGHES J, KIM YG, JEFFERSON JA, KANG DH, GORDON KL, LAN H Y, KIVLIGHN S, JOHNSON RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106. (Pubitemid 34252813)
90. KANG DH, NAKAGAWA T, FENG L, WATANABE S, HAN L, MAZZALI M, TRUONG L, HARRIS R, JOHNSON RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897. (Pubitemid 35386908)
91. SÁNCHEZ-LOZADA LG, TAPIA E, SANTAMARÍA J, AVILA-CASADO C, SOTO V, NEPOMUCENO T, RODRÍGUEZ-ITURBE B, JOHNSON RJ, HERRERA-ACOSTA J. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237-247. (Pubitemid 40019245)
92. GUSTAFSSON D, UNWIN R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrology 2013; 14: 164.
93. JOHNSON RJ, NAKAGAWA T, JALAL D, SÁNCHEZ-LOZADA LG, KANG DH, RITZ E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 2013; 28: 2221-2228.
94. SIU YP, LEUNG KT, TONG MK, KWAN TH Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59. (Pubitemid 41828266)
95. GOICOECHEA M, DE VINUESA SG, VERDALLES U, RUIZ-CARO C, AMPUERO J, RINCÓN A, ARROYO D, LUÑO J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-1393.
96. MOMENI A, SHAHIDI S, SEIRAFIAN S, TAHERI S, KHEIRI S. Effect of allopurinol in decreasing proteinuria in Type 2 diabetic patients. Iran J Kidney Dis 2010; 4: 128-132.
97. SHI Y, CHEN W, JALAL D, LI Z, CHEN W, MAO H, YANG Q, JOHNSON RJ, YU X. Clinical outcome of hyperuricemia in IgA nephropathy: A retrospective cohort study and randomized controlled trial. Kidney Blood Press Res 2012; 35: 153-160.
98. MIAO Y, OTTENBROS SA, LAVERMAN GD, BRENNER BM, COOPER ME, PARVING HH, GROBBEE DE, SHAHINFAR S, DE ZEEUW D, LAMBERS HEERSPINK HJ. Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin II antagonist losartan trial. Hypertension 2011; 58: 2-7.
99. RICÓS C, ALVAREZ V, CAVA F, GARCÍA-LARIO J V, HERNÁN-DEZ A, JIMÉNEZ C V, MINCHINELA J, PERICH C, SIMÓN M. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999; 59: 491-500. (Pubitemid 30056739)